Demonstrates a deep learning model that enhances Parkinson's disease classification using multimodal data, suggesting improved early diagnosis potential.
Background Parkinson’s disease (PD) is a prevalent neurodegenerative disorder that severely affects motor and cognitive functions. Early diagnosis, particularly during the prodromal phase, is critical for effective intervention. Methods This study presents MultimodalCNN-PD++, a deep learning model that integrates Magnetic Resonance Imaging (MRI) with clinical metadata (including motor/cognitive assessments, demographic data, and genetic biomarkers) to enhance PD classification. The model employs a lightweight EfficientNetB0 backbone, Mobile Convolutional Block Attention Modules (Mobile CBAM), and an enhanced Meta-Guided Cross-Attention (MGCA++) mechanism. A three-stage hierarchical feature selection method identifies the most discriminative clinical features, while metadata is processed with BioClinicalBERT using Low-Rank Adaptation (LoRA). Results Validated on the Parkinson’s Progression Markers Initiative (PPMI) dataset, the model achieved 97.5% accuracy in distinguishing Normal Control, prodromal PD, and diagnosed PD cases, with reduced parameters and computational costs. External validation on the OASIS-3 dataset confirmed robust generalizability (96.2% accuracy) despite demographic and acquisition protocol variations. Ablation studies highlighted the contributions of Mobile CBAM, MGCA++, hierarchical feature selection, and BioClinicalBERT-LoRA. Discussion This framework sets a new benchmark for multiclass PD diagnosis, demonstrating strong potential as a clinically deployable AI tool for early detection and personalized management of neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Zhi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: